Catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580]

In development
Reference number: GID-TA11774
Expected publication date: 30 September 2026

Documents

Documents created during the development process.

Invitation to participate

Final scope (PDF 123 KB)

Published:

28 October 2025
Final stakeholder list (PDF 136 KB)

Published:

28 October 2025
NICE's response to comments on the draft scope and provisional stakeholder list (PDF 156 KB)

Published:

28 October 2025
Equality impact assessment (scoping) (PDF 103 KB)

Published:

28 October 2025

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6580

Provisional stakeholder list post referral (PDF 153 KB)

Published:

25 July 2025
Draft scope post referral (PDF 150 KB)

Published:

25 July 2025